NCT07089251 The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery
| NCT ID | NCT07089251 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | King Abdullah International Medical Research Center |
| Condition | Knee Arthroplasty, Total |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2027-06-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2025-07-15 with a primary completion date of 2027-06-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this clinical trial is to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative blood loss, thromboembolic complications, and hospitalization duration in patients undergoing knee joint arthroplasty. Also aim to evaluate the effect of administering low-dose epinephrine and tranexamic acid on perioperative thromboembolic complications, and hospitalization duration
Eligibility Criteria
Inclusion Criteria: * Patients undergoing knee joint arthroplasty. * Saudi and Non-Saudi Patient. * Patients who have Complete medical record. Exclusion Criteria: * End stage renal disease * Liver cirrhosis * Coagulopathy * Pre-operative Hgb \<10 5. * History of cerebrovascular accident or myocardial infarction in past 12 months. * History of Heart failure. * History of arrhythmia. * History of pheochromocytoma, thyrotoxicosis and glaucoma. * Pregnancy or breast feeding * History of Deep venous thrombosis or pulmonary embolism * Allergy to epinephrine or tranexamic acid
Contact & Investigator
Wazzan Aljuhani, MD, FRCSC, MBA, MMEd
PRINCIPAL INVESTIGATOR
King Abdulaziz Medical City, MNGHA
Frequently Asked Questions
Who can join the NCT07089251 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Knee Arthroplasty, Total. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07089251 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07089251 currently recruiting?
Yes, NCT07089251 is actively recruiting participants. Contact the research team at althunayan.tu@hotmail.com for enrollment information.
Where is the NCT07089251 trial being conducted?
This trial is being conducted at Riyadh, Saudi Arabia.
Who is sponsoring the NCT07089251 clinical trial?
NCT07089251 is sponsored by King Abdullah International Medical Research Center. The principal investigator is Wazzan Aljuhani, MD, FRCSC, MBA, MMEd at King Abdulaziz Medical City, MNGHA. The trial plans to enroll 80 participants.